Back to News
Market Impact: 0.48
US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes
Source: reuters.com
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The FDA approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes. The approval provides an alternative to daily long-acting insulin injections and expands Lilly's diabetes-treatment portfolio, with potential benefits for patient convenience and treatment adherence.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
LLY0.82
More News
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes
- U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
- SEBI Allows Portfolio Managers to Invest Overseas, Short Equity Options
- Trump, Xi Address AI, Taiwan During State Visit
- Here’s the Tesla Semi… again